北美多发性硬化症治疗市场预测至 2027 年 - COVID-19 影响和按药物类别（免疫抑制剂和免疫调节剂）、给药途径（注射剂和口服）和分销渠道（医院药房、零售药房和电子商务）进行的区域分析
No. of Pages: 130 | Report Code: TIPRE00022633 | Category: Life Sciences
No. of Pages: 130 | Report Code: TIPRE00022633 | Category: Life Sciences
多发性硬化症（MS）是一种影响中枢神经系统的自身免疫性疾病。多发性硬化症是一种广泛存在的致残性神经系统疾病，大多数在 20-50 岁年龄段的人群中被诊断出来。这是一种潜在的使人衰弱的疾病，会导致身体的沟通和协调功能中断。
北美多发性硬化症治疗市场预计将从2019年的914498万美元增至2027年的1526974万美元；预计 2020 年至 2027 年复合年增长率为 6.8%。市场的增长归因于几个关键驱动因素，例如多发性硬化症患病率的增加和多发性硬化症研究资金的增加。然而，多发性硬化症治疗的高成本阻碍了市场的增长。
根据美国国家多发性硬化症协会 2017 年的研究，大约有 100 万成年人（高达 913,925 ）在美国患有多发性硬化症。因此，多发性硬化症患病率的不断上升正在推动北美多发性硬化症治疗市场的增长。由于资金的增加，正在开展广泛的研究，开发多发性硬化症的新药物和治疗方法，以及识别多发性硬化症潜在原因的其他方法。美国国家神经疾病和中风研究所、国家多发性硬化症协会和帕金森行动网络等各种组织正在开展广泛的努力，为多发性硬化症创造新的疗法，这正在推动市场的增长。
北美的 COVID-19 病例数量不断增加。患有神经系统疾病等慢性疾病的患者报告治疗延误。为了应对 COVID-19 大流行，多家公司正在削减临床试验活动并推迟产品发布。然而，在疫情期间，美国许多公司和研究机构正在主动研究COVID-19的神经系统表现。为了加速对 COVID-19 引起的神经系统并发症的诊断、预防和治疗的研究，已经启动了多项举措。这些因素在一定程度上对北美多发性硬化症治疗市场产生积极影响。
北美多发性硬化症治疗市场按药物类别分为免疫抑制剂和免疫调节剂。免疫调节剂细分市场在 2019 年占据了更大的市场份额，而免疫抑制剂细分市场预计在预测期内将实现更高的复合年增长率。
按给药途径北美多发性硬化症治疗市场分为注射剂和口服剂。注射剂细分市场在 2019 年占据了更大的市场份额，预计该细分市场在预测期内的市场复合年增长率将更高。
基于分销渠道北美多发性硬化症治疗市场分为医院药房、零售药房和电子商务。医院药房细分市场在 2019 年占据最大市场份额，而电子商务细分市场预计在预测期内的复合年增长率最高。
;
一些与本北美多发性硬化症治疗市场报告相关的主要和次要来源是卫生和预防部 (MoHAP)、美国疾病控制和预防中心 (CDC)、国家多发性硬化症协会和美国多发性硬化症协会 (MSAA) ).
北美多发性硬化症治疗市场细分
< strong>按分销渠道
Strategic insights for North America Multiple Sclerosis Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 9,144.98 Million |
| Market Size by 2027 | US$ 15,269.74 Million |
| Global CAGR (2020 - 2027) | 6.8% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 药物类别
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Multiple Sclerosis Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Multiple Sclerosis Therapeutics Market is valued at US$ 9,144.98 Million in 2019, it is projected to reach US$ 15,269.74 Million by 2027.
As per our report North America Multiple Sclerosis Therapeutics Market, the market size is valued at US$ 9,144.98 Million in 2019, projecting it to reach US$ 15,269.74 Million by 2027. This translates to a CAGR of approximately 6.8% during the forecast period.
The North America Multiple Sclerosis Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Multiple Sclerosis Therapeutics Market report:
The North America Multiple Sclerosis Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Multiple Sclerosis Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Multiple Sclerosis Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Multiple Sclerosis Therapeutics Market
